Want to join the conversation?
$K expects 2016 capital expenditure to be 4-5% of sales, including impact of cash required by Project K and rise in capital spending equal to about 1% of sales to support growth of Pringles business. Separately, $K said its BoD has approved a $1.5Bil share-repurchase program that will run through 2016 and 2017.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.